Log in with your email address username.


Important notice

doctorportal Learning is on the move as we will be launching a new website very shortly. If you would like to sign up to dp Learning now to register for CPD learning or to use our CPD tracker, please email support@doctorportal.com.au so we can assist you. If you are already signed up to doctorportal Learning, your login will work in the new site so you can continue to enrol for learning, complete an online module, or access your CPD tracker report.

To access and/or sign up for other resources such as Jobs Board, Bookshop or InSight+, please go to www.mja.com.au, or click the relevant menu item and you will be redirected.

All other doctorportal services, such as Find A Doctor, are no longer available.

[Comment] Triple therapy for symptomatic patients with COPD

Combination therapy is almost the standard for treating chronic diseases, including chronic obstructive pulmonary disease (COPD).1 Until 2016, the Global Initiative for Chronic Obstructive Lung Disease (GOLD) recommendation for highly symptomatic COPD patients at risk of exacerbations or severe airflow limitation (GOLD D) was treatment with either long-acting muscarinic antagonists (LAMA) or long-acting β2-agonists (LABA) in combination with inhaled glucocorticosteroids (ICS), both with strong evidence.